Active Stocks
Mon May 27 2024 15:59:11
  1. Tata Steel share price
  2. 175.50 0.40%
  1. NTPC share price
  2. 369.60 -1.40%
  1. State Bank Of India share price
  2. 834.10 0.66%
  1. HDFC Bank share price
  2. 1,527.95 0.75%
  1. ICICI Bank share price
  2. 1,129.15 -0.19%
Business News/ Companies / News/  China's Sinopharm says data 'better than expected' from it's COVID vaccine trial
BackBack

China's Sinopharm says data 'better than expected' from it's COVID vaccine trial

Sinopharm's unit CNBG has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the UAE, Bahrain and Egypt
  • It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from
  • Sinopharm (REUTERS)Premium
    Sinopharm (REUTERS)

    China National Pharmaceutical Group (Sinopharm) said on Wednesday the data from large-scale, late-stage clinical trials for its unit's COVID-19 vaccine are "better than expected".

    Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.

    The trials are nearing their ends, Sinopharm said in a statement on Chinese social media WeChat.

    It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from.


    You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!

    This story has been published from a wire agency feed without modifications to the text.

    Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
    More Less
    Published: 11 Nov 2020, 06:46 PM IST
    Next Story footLogo
    Recommended For You